Glucose and Lipid Metabolism on Antipsychotic Medication
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This project aims to a) evaluate the effects of selected antipsychotic medications on insulin
action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue
(whole-body lipolysis), b) evaluate the effects of selected antipsychotic medications on
abdominal adipose tissue mass, total body fat and total fat-free mass, and c) explore the
longitudinal effects of treatment with selected antipsychotics on glucose tolerance, lipid
profiles, abdominal adipose tissue mass, total body fat and total fat-free mass. These
hypotheses will be evaluated by measuring 1) whole-body glucose and lipid kinetics with the
use of "gold-standard" stable isotope tracer methodology, 2) body composition using dual
energy x-ray absorptiometry and magnetic resonance imaging, and 3) longitudinal changes in
glucose tolerance and lipid profiles. The aims will be addressed in non-diabetic
schizophrenia patients chronically treated with risperidone, olanzapine, clozapine,
quetiapine, ziprasidone, or haloperidol, and untreated healthy controls. Re-evaluations will
also be performed in patients who are randomized to switch from their current antipsychotic
(from the above groups) to risperidone, olanzapine, quetiapine, or ziprasidone for 6 months.
Relevant data is critically needed to target basic research, identify long-term
cardiovascular consequences, and plan therapeutic interventions.
Phase:
N/A
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Institute of Mental Health (NIMH) National Institutes of Health (NIH)